Tirzepatide: Chemical Properties
8 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: July 2026
Chemical Properties
| Formula | C225H348N48O68 |
| Molecular Weight | 4813.5 Da |
| Synonyms | Tirzepatide, LY3298176, Dual GIP/GLP-1 Receptor Agonist, GIP/GLP-1 RA |
| Cas Number | 2023788-19-2 |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser (Aib at positions 2 and 13; Lys20 conjugated to a gamma-Glu / C20 fatty-diacid moiety) |
| Pubchem Cid | 156588324 |
| Monoisotopic Mass | N/A |
| Polar Area | N/A |
| Complexity | N/A |
| X Log P | N/A |
| Heavy Atom Count | N/A |
| H Bond Donor Count | N/A |
| H Bond Acceptor Count | N/A |
| Rotatable Bond Count | N/A |
Identifiers
| Pubchem Cid | 156588324 |
| Inchi Key | N/A |
| Inchi | N/A - 39-amino acid synthetic peptide |
| Smiles Isomeric | N/A - 39-AA peptide (full structure via PubChem CID 156588324) |
| Smiles Canonical | N/A - 39-AA peptide (full structure via PubChem CID 156588324) |
| Iupac Name | Tirzepatide - 39-amino acid synthetic dual GIP/GLP-1 receptor agonist peptide |
Expert Observation
“(2018)Cell/rodent + phase 1First unimolecular dual GIP/GLP-1 receptor agonist; discovery-to-proof-of-concept characterization[1] Willard et al.”
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143-157.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
- Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.
- Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201-216.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.